NewcelX (NCEL) Retained Earnings (2019 - 2025)
NewcelX (NCEL) posted quarterly Retained Earnings of -$84.9 million for Q4 2025, down 10.84% year-over-year from -$95.2 million in Q4 2024, and up 3.24% quarter-over-quarter from -$87.7 million in Q2 2025.
NewcelX (NCEL) Retained Earnings (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Retained Earnings for 7 consecutive years, with -$84.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 10.84% year-over-year to -$84.9 million; the TTM figure through Dec 2025 stood at -$84.9 million (down 10.84% YoY), while the FY2025 annual figure was -$84.9 million, down 10.84% from the prior year.
- Retained Earnings grew to -$84.9 million in Q4 2025 per NCEL's latest filing, from -$87.7 million in the prior quarter.
- Across five years, Retained Earnings topped out at $42.1 million in Q4 2021 and bottomed at -$87.7 million in Q2 2025.
- Historically, Retained Earnings has averaged -$56.6 million across 5 years, with a median of -$68.7 million in 2023.
- Annual changes were most pronounced in 2021 — Retained Earnings surged 241.42% — and 2022, when it sank 257.02%.
- NewcelX's Retained Earnings stood at $42.1 million in 2021, then tumbled by 257.02% to -$66.1 million in 2022, then retreated by 4.94% to -$69.3 million in 2023, then declined by 10.45% to -$76.6 million in 2024, then dropped by 10.84% to -$84.9 million in 2025.
- Business Quant data shows NCEL's Retained Earnings at -$84.9 million in Q4 2025, -$87.7 million in Q2 2025, and -$76.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 4.38 Bn |
| 10 | NewcelX | 12.65 Mn | 10.45 Mn | - | -84.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -84.89 Mn |
| Jun 30, 2025 | -87.73 Mn |
| Dec 31, 2024 | -76.59 Mn |
| Jun 30, 2024 | -70.58 Mn |
| Dec 31, 2023 | -69.35 Mn |
| Jun 30, 2023 | -68.00 Mn |
| Dec 31, 2022 | -66.08 Mn |
| Jun 30, 2022 | -50.35 Mn |
| Dec 31, 2021 | 42.08 Mn |
| Jun 30, 2021 | -34.36 Mn |
| Dec 31, 2020 | -29.76 Mn |
| Dec 31, 2019 | -26.90 Mn |